Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508 covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.
The patent grant is a significant milestone for the company as it advances its biotechnology division. Klotho is a protein associated with longevity and neuroprotection, and its expression through gene therapy holds promise for treating neurodegenerative conditions. By securing patent protection in Australia, Greenland Mines fortifies its position in a key market and adds to its global intellectual property portfolio. This development is particularly important for the KLTO-202 program, which is focused on ALS, a devastating disease with limited treatment options. The patent covers various aspects of the therapy, including delivery systems, which are critical for effective treatment.
Greenland Mines operates two divisions: Mining, focused on exploration and development of the Skaergaard Project in Greenland and the Sarfartoq rare earths project, and Biotech, including the Klotho-based KLTO-202 program. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its North Atlantic Critical Metals Corridor vision. This dual-focus approach allows the company to leverage synergies between its mining and biotech operations.
For more details, the full press release is available at https://nnw.fm/PVbbH. The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
Forward-looking statements in this article involve risks and uncertainties that may cause actual results to differ materially. These are detailed in the company's filings with the SEC. All parties undertake no duty to update this information unless required by law.
